Imperial College London
Alternate

ProfessorSejalSaglani

Faculty of Medicine, National Heart & Lung Institute

Professor of Paediatric Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3167s.saglani

 
 
//

Location

 

112Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Scotney:2021:10.1111/pai.13543,
author = {Scotney, E and Burchett, S and Goddard, T and Saglani, S},
doi = {10.1111/pai.13543},
journal = {Pediatric Allergy and Immunology},
pages = {1405--1415},
title = {Pediatric problematic severe asthma: Recent advances in management},
url = {http://dx.doi.org/10.1111/pai.13543},
volume = {32},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Problematic severe asthma remains a significant challenge to manage, accounting for the majority of healthcare utilization among children with asthma. The heterogeneity is recognized and the clinical phenotypes of “difficult-to-treat” asthma (DA) and “severe therapy-resistant asthma” (STRA) help to guide management. Recent evidence supports molecular distinctions between these phenotypes and shows poor correlations between peripheral and airway markers of inflammation, especially in STRA. Airway neutrophils in the context of childhood severe asthma have been explored, but their role in disease causation, protection, or as bystanders remain unknown, and thus, treatment implications are unclear. Several novel management strategies, including once-daily maintenance therapy, single-device maintenance and reliever therapy, and novel biological treatments are being increasingly used for DA and STRA. However, pediatric data for efficacy of novel treatments is scarce, and when available, is restricted to adolescents. The aim of this review is to highlight recent advances in objective biomarkers that aid stratification and management of childhood severe asthma and to highlight gaps in pediatric evidence. Specifically, the urgent need for efficacy studies to improve the management of problematic severe asthma in children younger than 12 years.
AU  - Scotney,E
AU  - Burchett,S
AU  - Goddard,T
AU  - Saglani,S
DO  - 10.1111/pai.13543
EP  - 1415
PY  - 2021///
SN  - 0905-6157
SP  - 1405
TI  - Pediatric problematic severe asthma: Recent advances in management
T2  - Pediatric Allergy and Immunology
UR  - http://dx.doi.org/10.1111/pai.13543
UR  - http://hdl.handle.net/10044/1/89802
VL  - 32
ER  -
Download